GlaxoSmithKline PLC (NYSE:GSK)

37.33
Delayed Data
As of 4:02pm ET
 -0.37 / -0.98%
Today’s Change
34.52
Today|||52-Week Range
44.54
+5.24%
Year-to-Date
Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles
Feb 16 / TheStreet.com - Paid Partner Content
Glaxo's (GSK) Begins Phase III HIV Two-Drug Regimen Study
Feb 09 / Zacks.com - Paid Partner Content
Dodge & Cox Comments on GlaxoSmithKline
Feb 13 / GuruFocus News - Paid Partner Content
Glaxo (GSK) Earnings and Revenues Surpass Estimates in Q4
Feb 08 / Zacks.com - Paid Partner Content
Dodge & Cox 4th Quarter Commentary
Feb 13 / GuruFocus News - Paid Partner Content
FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up
Feb 08 / Zacks.com - Paid Partner Content
Foreign Stock Roundup: TOT, STO & GSK Earnings Impress, BP & SNY Disappoint
Feb 12 / Zacks.com - Paid Partner Content
Glaxo (GSK) Stock Down Despite Q4 Earnings and Sales Beat
Feb 07 / Zacks.com - Paid Partner Content